1. Articles from biospace.com

  2. 1-24 of 50 1 2 »
    1. Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals US

      Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals US

      DURHAM, N.C., May 30, 2019 /PRNewswire/ -- Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of Directors. Jack Bailey, President, US Pharmaceuticals at GlaxoSmithKline, joined the Board on May 17, 2019. Moise Khayrallah, PhD, CEO and Chairman of the Board, Meg Powell, PharmD, Co-Founder of Target Pharma Solutions, and Bobby Helmedag, Managing Director, Rex Health Ventures, will continue to serve with Bailey...

      Read Full Article
    2. Eiger BioPharmaceuticals Appoints Biotech Veteran Amit K. Sachdev to Board of Directors

      Eiger BioPharmaceuticals Appoints Biotech Veteran Amit K. Sachdev to Board of Directors

      PALO ALTO, Calif., April 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board of Directors...

      Read Full Article
    3. Pulse Biosciences Appoints Mitchell Levinson to Board of Directors

      Pulse Biosciences Appoints Mitchell Levinson to Board of Directors

      HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.(NASDAQ:PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee...

      Read Full Article
    4. Axonics® Appoints Michael H. Carrel to its Board of Directors

      Axonics® Appoints Michael H. Carrel to its Board of Directors

      IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointed to the Axonics board of directors, effective immediately...

      Read Full Article
    5. Henry Schein and Vets First Choice Announce Board of Directors for Covetrus

      Henry Schein and Vets First Choice Announce Board of Directors for Covetrus

      ( BUSINESS WIRE )-- Henry Schein, Inc. (Nasdaq: HSIC) and Vets First Choice today announced their designees who will comprise the 11-member board of directors for Covetrus, the new standalone public company that will result from the planned spin-off of the Henry Schein Animal Health business and the subsequent merger with Vets First Choice...

      Read Full Article
    6. Homology Medicines Appoints Matthew R. Patterson to Board of Directors

      Homology Medicines Appoints Matthew R. Patterson to Board of Directors

      BEDFORD, Mass., Jan. 17, 2018 /PRNewswire/ -- Homology Medicines, a genetic medicines company, announced today the appointment of Matthew R. Patterson, Co-Founder, President and Chief Executive Officer of Audentes Therapeutics, to Homology's Board of Directors . Mr. Patterson is a biotech ...

      Read Full Article
    7. Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva

      Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva

      Shares of Teva Pharmaceuticals are up more than 5 percent this morning after Israeli media reported billionaire businessman Len Blavatnik is considering taking a large stock position in the pharma giant. Citing multiple Israeli media outlets, Reuters reported Blavatnik “has been examining a large share purchase in Teva.” According to reports, Blavatnik could invest up to $3 billion in Teva...

      Read Full Article
    8. Why Ex-Ariad CEO Joining This Biotech's Board Could Mean a Buyout Deal Is Coming

      Why Ex-Ariad CEO Joining This Biotech's Board Could Mean a Buyout Deal Is Coming

      The former CEO of Ariad Pharmaceuticals Inc., who spent the last year shaping up the Cambridge-based drug company for its $5.2 acquisition earlier this year, was just named to the board of a new biotech last week. There, as the newest board member of New Jersey-based The Medicines Company, Paris Panayiotopoulos joins a familiar face: Alex Denner, former chairman of Ariad (Nasdaq: ARIA)...

      Read Full Article
      Mentions: MDC Partners
    9. Kite Pharma Announces Appointment Of Renowned Cancer Researcher, M.D., To Its Board Of Directors

      Kite Pharma Announces Appointment Of Renowned Cancer Researcher, M.D., To Its Board Of Directors

      Kite Pharma, Inc. today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles and a renowned cancer researcher, has been appointed to its Board of Directors...

      Read Full Article
    10. Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board

      Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board

      Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), a privately-held, clinical stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, announced today that it has completed the second tranche of its previously disclosed $80 million private financing...

      Read Full Article
    1-24 of 50 1 2 »
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content